The predictive variables assessed were age at EGPA diagnosis, baseline eosinophil count, history of chronic sinusitis prior to diagnosis, and glucocorticoid-treated asthma at diagnosis.

Ocrevus (ocrelizumab) and Tysabri (natalizumab) appear equally effective at controlling relapses and MS progression, a study ...

An existing drug currently used to treat glaucoma, altitude sickness, and seizures may also have the potential to prevent ...

Real-world data show Ocrevus reduced relapse rates and maintained disability stability in relapsing MS over four years.

American Addiction Centers (AAC), a leading provider of addiction treatment, has launched AAC Together, a new alumni app ...

CareDx (NASDAQ:CDNA) used an investor webcast to outline its “Transplant Plus” expansion into cell therapy and to highlight ...

For decades, prevailing wisdom held that to overcome addiction, the most important thing to do was to flush or “clean” the drugs out of one’s system, to get a fresh start. But more and more, research ...

Relapse rates over 3 years did not differ with glucocorticoid withdrawal vs maintenance among patients with stable SjD-ILD.

Investigators sought to determine whether adjuvant pembrolizumab is associated with the risk of developing subsequent cutaneous malignant neoplasms in patients with high-risk stage II melanoma.

Objectives Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is a systemic autoimmune disease where infections ...

Despite great progress in curing childhood acute lymphoblastic leukemia (ALL), survival after relapse remains poor. We analyzed survival after relapse among 9585 pediatric patients enrolled on ...